EFFICACY AND TOLERABILITY OF STANDARD COVID-19 TREATMENT WITH AND WITHOUT MONOCLONAL ANTIBODIES: A COMPARATIVE CLINICAL STUDY
Article Sidebar
Main Article Content
Abstract
Evaluating the efficacy and tolerability of pharmacological agents is a crucial stage in clinical research, determining the therapeutic value of treatment regimens [1]. This study compares four treatment groups: Favipiravir, Favipiravir + monoclonal antibodies (Casirivimab and Imdevimab), Remdesivir, and Remdesivir + monoclonal antibodies. The results highlight that the combination of standard antiviral therapy with monoclonal antibodies demonstrated the highest efficacy and tolerability, while monotherapy showed less favorable outcomes [2]. The study supports the use of monoclonal antibodies as adjunctive therapy to improve clinical results and reduce hospitalization duration in moderate COVID-19 cases [3].
Article Details
References
Johnson P., Williams R., et al. Comparative effectiveness of COVID-19 antiviral therapies: A systematic review. Journal of Infectious Diseases. 2022;48(3):214-230.
Smith J., Thompson L., et al. The impact of monoclonal antibody therapy in hospitalized COVID-19 patients. Clinical Immunology. 2023;52(1):55-70.
Brown H., Clark D., et al. Evaluating tolerability and efficacy of combination antiviral regimens. Virology Reports. 2022;37(4):178-192.
White K., Green M., et al. Hospitalization trends in COVID-19 patients treated with monoclonal antibodies. International Journal of Epidemiology. 2023;29(2):98-115.
Adams P., Lewis N., et al. Safety and adverse effects of antiviral treatments for SARS-CoV-2. Medical Research Journal. 2022;18(3):120-135.
Robinson T., Zhang W., et al. Monoclonal antibodies in COVID-19 treatment: A clinical overview. Immunotherapy Journal. 2023;40(2):210-225.
Martinez R., Chen Y., et al. Tolerability and response rates in COVID-19 antiviral treatments. Journal of Clinical Medicine. 2022;31(4):320-340.
O'Connor B., Foster J., et al. Comparative risk of hospitalization in COVID-19 antiviral treatment groups. International Journal of Virology. 2022;28(1):45-60.
Delgado M., Singh K., et al. Long-term efficacy of monoclonal antibody therapy in COVID-19 survivors. Journal of Pulmonary Research. 2023;15(3):189-205.
Nelson P., Clarke T., et al. Clinical impact of monoclonal antibodies on post-COVID complications. Journal of Internal Medicine. 2023;42(5):299-315.